Pharming Group (NASDAQ:PHAR) Short Interest Up 107.1% in March

Pharming Group (NASDAQ:PHAR - Get Free Report) was the recipient of a large increase in short interest in March. As of March 15th, there was short interest totalling 5,800 shares, an increase of 107.1% from the February 28th total of 2,800 shares. Approximately 0.0% of the company's shares are sold short. Based on an average daily volume of 6,700 shares, the short-interest ratio is presently 0.9 days.

Institutional Trading of Pharming Group

A hedge fund recently raised its stake in Pharming Group stock. Silverberg Bernstein Capital Management LLC lifted its holdings in Pharming Group (NASDAQ:PHAR - Free Report) by 16.8% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 47,997 shares of the company's stock after purchasing an additional 6,887 shares during the period. Silverberg Bernstein Capital Management LLC owned 0.07% of Pharming Group worth $483,000 at the end of the most recent reporting period. Hedge funds and other institutional investors own 0.03% of the company's stock.

Analysts Set New Price Targets

A number of analysts have recently issued reports on PHAR shares. Oppenheimer increased their target price on Pharming Group from $30.00 to $39.00 and gave the company an "outperform" rating in a report on Friday, March 14th. Jefferies Financial Group began coverage on Pharming Group in a research report on Monday, December 9th. They set a "buy" rating and a $14.00 price objective for the company. Finally, HC Wainwright reiterated a "buy" rating and issued a $37.00 target price on shares of Pharming Group in a report on Thursday, March 20th.

Remove Ads

Pharming Group Stock Down 1.9 %

Shares of NASDAQ:PHAR traded down $0.16 during midday trading on Tuesday, hitting $8.21. 2,687 shares of the stock were exchanged, compared to its average volume of 6,415. The business's fifty day simple moving average is $8.77 and its two-hundred day simple moving average is $8.69. The company has a debt-to-equity ratio of 0.41, a quick ratio of 2.76 and a current ratio of 3.53. Pharming Group has a 52-week low of $6.65 and a 52-week high of $11.30. The company has a market capitalization of $558.53 million, a PE ratio of -31.58 and a beta of -0.10.

Pharming Group (NASDAQ:PHAR - Get Free Report) last announced its quarterly earnings results on Thursday, March 13th. The company reported $0.05 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.07 by ($0.02). The firm had revenue of $92.70 million for the quarter, compared to analyst estimates of $76.67 million. Pharming Group had a negative net margin of 6.09% and a negative return on equity of 7.65%. As a group, research analysts predict that Pharming Group will post -0.2 earnings per share for the current fiscal year.

Pharming Group Company Profile

Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome.